Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens.

Muir AJ, Gong L, Johnson SG, Michael Lee MT, Williams MS, Klein TE, Caudle KE, Nelson DR.

Source

Division of Gastroenterology, Department of Medicine, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.

Abstract

PEG-interferon-α and ribavirin based regimens are the mainstay for treatment of Hepatitis C Virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-interferon-α and ribavirin therapy in previously untreated patients and can be used by patients and clinicians as part of shared decision making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-interferon-α and ribavirin containing regimens based on IFNL3 genotype.Clinical Pharmacology & Therapeutics (2013); accepted article preview online 4 October 2013 doi:10.1038/clpt.2013.203.